Red blood cells from pluripotent stem cells for use in transfusion.
The use of donated red blood cells in transfusion is a well-established cellular therapy. However, problems including insufficient supply, transfusion-transmitted infections and the need for immunological matching hamper even in the best services. These issues may be eliminated by using pluripotent stem cells to generate universal donor group O, Rhesus D-negative red blood cells. Human embryonic stem cells can be maintained and expanded indefinitely and can, therefore, produce the very large cell numbers required for this application. Red blood cell production is also an attractive goal for pluripotent stem cell-derived therapeutics because it is a well-characterized single cell suspension, lacking nucleated cells and with a low expression of HLA molecules. Much progress has been made; however, a number of challenges remain including scale-up, clinical effectiveness and product safety.
Mountford
Joanne C
JC
Faculty of Biomedical & Life Sciences, University of Glasgow, University Avenue, Glasgow, G12 8QQ, UK. j.mountford@bio.gla.ac.uk
Olivier
Emmanuel
E
Jordanides
Niove E
NE
de Sousa
Paul
P
Turner
Marc L
ML
D001771:Blood Banks; D002454:Cell Differentiation; D002986:Clinical Trials as Topic; D018920:Coculture Techniques; D053595:Embryonic Stem Cells / Q000166:cytology*; D017707:Erythrocyte Transfusion / Q000295:instrumentation* / Q000379:methods*; D004912:Erythrocytes / Q000166:cytology*; D006410:Hematopoiesis / Q000502:physiology*; D006412:Hematopoietic Stem Cells / Q000166:cytology; D006801:Humans; D039904:Pluripotent Stem Cells / Q000166:cytology*; D044968:Regenerative Medicine / Q000379:methods